Our commitment to being the leader in responsible pain management
Collegium Pharmaceutical is a specialty pharmaceutical company committed to being the leader in responsible pain management. For nearly two decades, Collegium has been focused on developing and commercializing new medicines for pain management that reflect our Core Values and our commitment to people suffering from pain, providers and our communities. The result of those efforts is a portfolio of meaningfully differentiated medications to treat moderate to severe pain.
Acute and chronic pain impact millions of Americans every year
There are two broad categories of pain: acute pain, or pain that is self-limited and generally requires treatment for no more than a few months, and chronic pain, or pain that lasts beyond the healing of an injury or that persists longer than three to six months. Between 50-100 million adults in the U.S. are affected by chronic pain each year, and as many as 19.6 million of those adults experience high-impact chronic pain that interferes with daily life or work activities. Prescription opioids continue to serve as important tools in the treatment of acute and chronic pain where alternative treatments have proven inadequate.
Opioid abuse is an epidemic in the United States
The misuse, abuse and diversion of prescription opioids have contributed to today’s opioid crisis. In 2017, the CDC estimated that prescription drug overdoses claimed the lives of more than 17,000 people in the U.S.
Statistics for pain and pain management in the United States
U.S. adults annually experience chronic pain
of those with chronic pain experience high-impact pain
$560 billion +
in healthcare and productivity costs each year linked to chronic pain
Addressing the Opioid Epidemic
Striking the right balance between providing access for legitimate and well-supervised patients to innovative and effective therapies and protecting our communities from the significant risks associated with opioid misuse, abuse and diversion is a critical part of our mission at Collegium. We believe that, until innovation obviates the need for opioid therapies, differentiated products and responsible engagement by pharmaceutical companies can play an important role in addressing our nation’s opioid abuse epidemic.
Today, we have a portfolio of innovative and differentiated pain medicines, supported by a team of professionals dedicated to fostering responsible pain management. We recognize that it is about more than medicine: it is about people suffering from pain, providers, communities and the entire ecosystem in which we operate.